Related Experiment Video

Updated: Aug 13, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis

G Garibotto1, N Acquarone, S Saffioti

  • 1Istituto Scientifico di Medicina Interna, University of Genoa, Italy.

Nephron
|January 1, 1989
PubMed

Insights

Plasmapheresis may reverse kidney damage in patients with hemolytic uremic syndrome (HUS) caused by mitomycin C (MMC). This treatment offers a potential avenue for improving renal function in affected individuals.

Area of Science:

  • Nephrology
  • Oncology
  • Hematology

Background:

  • Mitomycin C (MMC) is an antineoplastic agent that can induce hemolytic uremic syndrome (HUS).
  • HUS is a severe condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.
  • Therapeutic interventions for MMC-induced HUS have historically shown limited success in reversing renal failure.

Observation:

  • A patient developed HUS following mitomycin C administration.
  • Renal biopsy revealed pathologic changes consistent with thrombotic microangiopathy.
  • Standard therapeutic attempts to manage renal failure were unsuccessful.

Findings:

  • Treatment with plasmapheresis was initiated for the patient with MMC-induced HUS.
  • The patient experienced a favorable clinical outcome.
  • Significant recovery of renal function was observed post-plasmapheresis.

Implications:

  • Plasmapheresis represents a promising therapeutic option for MMC-induced HUS.
  • This modality should be strongly considered in the management of patients presenting with this condition.
  • Further research may elucidate the precise mechanisms of plasmapheresis in mitigating HUS-associated renal damage.

More Related Videos

Use of the Soft-agar Overlay Technique to Screen for Bacterially Produced Inhibitory Compounds06:38

Use of the Soft-agar Overlay Technique to Screen for Bacterially Produced Inhibitory Compounds

Published on: January 14, 2017

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...